Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
March 5, 2024
Assignee:
UCB BIOPHARMA SRL
Inventors:
Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
Abstract: The present invention relates generally to compositions for treating patients that have skin cancer or have recently had skin cancers removed. More specifically, the present invention provides human skin substitutes engineered to express exogenous IL-12 and compositions and methods for making human skin substitutes engineered to express exogenous IL-12. In addition, the present invention provides methods for treatment of sites on a patient where skin cancers have been removed with human skin substitutes engineered to express exogenous IL-12.
Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
January 2, 2024
Assignee:
Synthekine, Inc.
Inventors:
Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
December 5, 2023
Assignee:
BIOATLA, INC.
Inventors:
Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
Type:
Grant
Filed:
September 29, 2020
Date of Patent:
October 3, 2023
Assignee:
Merck Patent GmbH
Inventors:
Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
Abstract: The present invention provides a tumour vasculature permeabilising molecule for use in permeabilising vasculature of a tumour for treating, detecting or diagnosing said tumour wherein said tumour vasculature permeabilising molecule is formulated for systemic administration to said patient. A composition comprising a tumour vasculature permeabilising molecule and an appropriate anticancer agent or imaging agent, and a method of treatment or a method of detecting the presence or absence of a tumour are also provided.
Type:
Grant
Filed:
December 8, 2010
Date of Patent:
September 5, 2023
Assignee:
OXFORD UNIVERSITY INNOVATION LIMITED
Inventors:
Daniel Anthony, Nicola Sibson, Len Seymour, Kerry Fisher
Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
July 4, 2023
Assignees:
Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio Scientific
Inventors:
Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
May 16, 2023
Assignee:
Eli Lilly and Company
Inventors:
Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
Type:
Grant
Filed:
August 3, 2018
Date of Patent:
January 3, 2023
Assignee:
Amgen Inc.
Inventors:
Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Darren Bates, Marissa Mock, Shunsuke Takenaka
Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
December 27, 2022
Assignee:
NOVARTIS AG
Inventors:
Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Type:
Grant
Filed:
March 19, 2020
Date of Patent:
December 27, 2022
Assignee:
NOVARTIS AG
Inventors:
Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
December 20, 2022
Assignee:
Boston Pharmaceuticals Inc.
Inventors:
Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
Abstract: The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can farther include other interleukins such as IL-1?, and IL-1? can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.
Type:
Grant
Filed:
April 23, 2020
Date of Patent:
December 6, 2022
Assignee:
Georgia State University Research Foundation, Inc.
Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
Type:
Grant
Filed:
September 8, 2020
Date of Patent:
November 22, 2022
Assignee:
AMGEN K-A, INC.
Inventors:
Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
November 8, 2022
Assignee:
UCB BIOPHARMA SRL
Inventors:
Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
September 20, 2022
Inventors:
Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernykh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Timofey Aleksandrovich Nemankin, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov, Victoria Mikhailovna Ekimova, Ekaterina Vladimirovna Sofronova, Yakov Yurevich Ustyugov
Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
September 6, 2022
Assignee:
Genentech Inc.
Inventors:
ChinYu Lin, Theodore A. Omachi, Ryan P. Owen, Karl Yen, Yanan Zheng, Kendra Debusk
Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.
Type:
Grant
Filed:
May 11, 2021
Date of Patent:
September 6, 2022
Assignee:
Invetx, Inc.
Inventors:
William Brondyk, Brett Chevalier, Juergen Horn, Madhusudan Natarajan